secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001213900-24-021981
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara reports Q4 net loss of $10.2M; cash $65.6M; TARA-002 data milestones in 2024
--------------------------------------------------------------------------------

- Net loss Q4 2023: $10.2M ($0.90/share); full-year net loss $40.4M ($3.57/share).
- Cash, equivalents & investments $65.6M as of Dec 31, 2023; runway into Q2 2025.
- R&D expenses Q4 $6.4M (up from $5.0M YoY); full-year $25.0M (up from $16.8M).
- Preliminary ADVANCED-1EXP TARA-002 data in NMIBC CIS expected 1H 2024; ADVANCED-2 data in 2H 2024.
- Dosing underway in STARBORN-1 Phase 2 trial of TARA-002 for lymphatic malformations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024021981/0001213900-24-021981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024021981/ea0201584-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-021981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer